中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
1期
1-3
,共3页
2型糖尿病%冠心病%内脂素%阿托伐他汀%老年
2型糖尿病%冠心病%內脂素%阿託伐他汀%老年
2형당뇨병%관심병%내지소%아탁벌타정%노년
Type 2 diabetes%Coronary heart disease%Visfatin%Atorvastatin%Elderly
目的 探讨阿托伐他汀对2型糖尿病(T2DM)合并冠心病患者的干预作用.方法 将60例T2DM合并冠心病老年患者随机分为两组.对照组30例给予降糖及治疗冠心病治疗,观察组30例给予阿托伐他汀治疗;测定给药前后血清内脂素含量及血脂、血流变指标.结果 治疗前两组血脂指标比较差异无统计学意义(P＞0.05);对照组治疗前后血脂指标比较差异无统计学意义(P＞0.05);观察组治疗后三酰甘油、低密度脂蛋白水平较治疗前和对照组治疗后明显降低,高密度脂蛋白明显升高,差异有统计学意义(P＜0.05),总胆固醇治疗前后比较差异无统计学意义(P＞0.05).治疗6个月后,两组患者的全血黏度明显降低,且观察组改善情况显著优于对照组,差异有统计学意义(P＜0.05).治疗前两组血清内脂素及稳态胰岛素评价指数(Homa-IR)比较差异无统计学意义(P＞0.05);两组治疗后血清内脂素及Homa-IR与治疗前比较显著下降,差异有统计学意义(P＜0.05);观察组治疗后内脂素及Homa-IR较对照组治疗后明显降低,差异有统计学意义(P＜0.05).结论 血清内脂素是T2DM合并冠心病的高危因素,他汀类药物阿托伐他汀可降低血清中内脂素含量,进而降低Homa-IR的含量,延缓疾病发展.
目的 探討阿託伐他汀對2型糖尿病(T2DM)閤併冠心病患者的榦預作用.方法 將60例T2DM閤併冠心病老年患者隨機分為兩組.對照組30例給予降糖及治療冠心病治療,觀察組30例給予阿託伐他汀治療;測定給藥前後血清內脂素含量及血脂、血流變指標.結果 治療前兩組血脂指標比較差異無統計學意義(P＞0.05);對照組治療前後血脂指標比較差異無統計學意義(P＞0.05);觀察組治療後三酰甘油、低密度脂蛋白水平較治療前和對照組治療後明顯降低,高密度脂蛋白明顯升高,差異有統計學意義(P＜0.05),總膽固醇治療前後比較差異無統計學意義(P＞0.05).治療6箇月後,兩組患者的全血黏度明顯降低,且觀察組改善情況顯著優于對照組,差異有統計學意義(P＜0.05).治療前兩組血清內脂素及穩態胰島素評價指數(Homa-IR)比較差異無統計學意義(P＞0.05);兩組治療後血清內脂素及Homa-IR與治療前比較顯著下降,差異有統計學意義(P＜0.05);觀察組治療後內脂素及Homa-IR較對照組治療後明顯降低,差異有統計學意義(P＜0.05).結論 血清內脂素是T2DM閤併冠心病的高危因素,他汀類藥物阿託伐他汀可降低血清中內脂素含量,進而降低Homa-IR的含量,延緩疾病髮展.
목적 탐토아탁벌타정대2형당뇨병(T2DM)합병관심병환자적간예작용.방법 장60례T2DM합병관심병노년환자수궤분위량조.대조조30례급여강당급치료관심병치료,관찰조30례급여아탁벌타정치료;측정급약전후혈청내지소함량급혈지、혈류변지표.결과 치료전량조혈지지표비교차이무통계학의의(P＞0.05);대조조치료전후혈지지표비교차이무통계학의의(P＞0.05);관찰조치료후삼선감유、저밀도지단백수평교치료전화대조조치료후명현강저,고밀도지단백명현승고,차이유통계학의의(P＜0.05),총담고순치료전후비교차이무통계학의의(P＞0.05).치료6개월후,량조환자적전혈점도명현강저,차관찰조개선정황현저우우대조조,차이유통계학의의(P＜0.05).치료전량조혈청내지소급은태이도소평개지수(Homa-IR)비교차이무통계학의의(P＞0.05);량조치료후혈청내지소급Homa-IR여치료전비교현저하강,차이유통계학의의(P＜0.05);관찰조치료후내지소급Homa-IR교대조조치료후명현강저,차이유통계학의의(P＜0.05).결론 혈청내지소시T2DM합병관심병적고위인소,타정류약물아탁벌타정가강저혈청중내지소함량,진이강저Homa-IR적함량,연완질병발전.
Objective To investigate the intervention effects of atorvastatin on type 2 diabetes mellitus(T2DM) combined with coronary heart disease in elderly patients.Methods Sixty patients with T2DM combined with coronary heart disease were randomly divided into two groups.Thirty cases in control group were given hypoglycemic and treatment of coronary heart disease,30 cases in observation group were given atorvastatin treatment.Serum visfatin levels and blood lipid,blood rheology were measured before and after treatment.Results The blood indexes had no statistical significance between the two groups before treatment (P ＞ 0.05).The blood lipid indexes had no significant difference before and after treatment in control group (P ＞ 0.05).In the observation group,triglyceride and low density lipoprotein levels significantly decreased after the treatment compared with before treatment and control group,the high density lipoprotein increased obviously,the differences were statistically significant(P ＜ 0.05),and there were no significant differences in total cholesterol before and after treatment(P ＞ 0.05).After 6 months of treatment,blood viscosity of in the two groups decreased significantly,and that in the observation group improved more significantly than that in the control group(P ＜ 0.05).The serum visfatin and Homa-IR index had no statistical significance in the two groups before treatment (P ＞ 0.05).Serum visfatin and Homa-IR index decreased significantly after treatment than before treatment in the two groups(P ＜ 0.05).In the observation group,visfatin and Homa-IR index decreased significantly compared with the control group after treatment(P ＜ 0.05).Conclusions Serum visfatin is the high risk factor of T2DM combined with coronary heart disease,atorvastatin can decrease serum visfatin levels,thereby reduce the content of Homa-IR,delay development of the disease.
